Reduced folate receptor alpha (FOLR1) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab‐soravtansine therapy

Abstract Mirvetuximab‐soravtansine (MIRV‐S) is an antibody‐drug conjugate targeting folate receptor alpha (FOLR1). MIRV‐S is approved for the treatment of FOLR1‐positive, platinum‐resistant ovarian carcinoma. Patient eligibility is determined by immunohistochemistry (IHC) using a companion diagnosti...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Annika Nasdala, Leonie D Kandt, Martin Radner, Nora Schaumann, Malte Gronewold, Pia Hillmann, Henriette Christgen, Jens Hachenberg, Elna Kuehnle, Christian Hartmann, Matthias Christgen
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2026-05-01
Rangatū:	The Journal of Pathology: Clinical Research
Ngā marau:	ovarian carcinoma standardized controls reference materials immunohistochemistry folate receptor alpha (FOLR1)
Urunga tuihono:	https://doi.org/10.1002/2056-4538.70091
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!